CompletedNCT02962765

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Octapharma
Principal Investigator: Kate Khair, PhD
Great Ormond Street Hospital
Enrollment: 80 enrolled
Eligibility: MALE
Timeline: 2015 – 2020

Study locations (30)

University of Florida, Gainesville, Florida, United States
Nicklaus Children's Hospital, Miami, Florida, United States
Tulane University, New Orleans, Louisiana, United States
Hemophilia Treatment Center of Nevada, Las Vegas, Nevada, United States
Gulf States Hemophilia and Thrombophilia, Houston, Texas, United States
Centro de Tratamiento de la Hemofilia Cordoba, Córdoba, Argentina
CTH Centro de Tratamiento de Hematologia y Hemoterapia Córdoba S.A., Córdoba, Argentina
Fundación de Hemofilia de Salta, Salta, Argentina
Centro Mayo, Santiago del Estero, Argentina
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Borovlyany, Belarus
Fakultní nemocnice Brno, Brno, Czechia
Blood Centre, University Hospital, Ostrava, Czechia
Hospital de Especialidades Teodoro Maldonado Carbo, Guayaquil, Ecuador
CHU Hôtel Dieu, Nantes, France
Hopital Pontchaillou, Rennes, France
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02962765 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials